Qiagen (NYSE:QGEN) Announces Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Qiagen (NYSE:QGEN) posted its quarterly earnings data on Wednesday. The company reported $0.61 earnings per share for the quarter, topping the consensus estimate of $0.60 by $0.01, Zacks reports. Qiagen had a return on equity of 13.43% and a net margin of 4.73%. Qiagen updated its Q1 2025 guidance to 0.500- EPS and its FY 2025 guidance to 2.280- EPS.

Qiagen Stock Performance

Shares of QGEN traded down $1.51 on Friday, reaching $40.93. 484,844 shares of the company’s stock traded hands, compared to its average volume of 1,201,888. The company has a current ratio of 2.17, a quick ratio of 1.89 and a debt-to-equity ratio of 0.39. The stock has a market cap of $9.08 billion, a PE ratio of 102.13, a PEG ratio of 3.10 and a beta of 0.36. Qiagen has a 52-week low of $40.15 and a 52-week high of $49.30. The stock’s 50 day simple moving average is $43.80 and its two-hundred day simple moving average is $43.25.

Analysts Set New Price Targets

Several research firms recently issued reports on QGEN. Hsbc Global Res raised shares of Qiagen to a “hold” rating in a research report on Thursday, October 17th. Jefferies Financial Group reissued a “buy” rating and set a $52.50 price objective (up from $40.83) on shares of Qiagen in a report on Tuesday, December 10th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $46.67 price target (down from $48.61) on shares of Qiagen in a research note on Monday, January 6th. HSBC cut Qiagen from a “buy” rating to a “hold” rating and set a $47.64 target price for the company. in a research note on Thursday, October 17th. Finally, UBS Group cut their price target on Qiagen from $50.00 to $48.00 and set a “neutral” rating on the stock in a report on Friday. Five research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $49.84.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.